Joe Talamo

Today, we shared a positive data update from three pancreatic cancer arms of our ongoing Phase 2a trial of our lead program, IMM-1-104. This marks another encouraging milestone, reinforcing IMM-1-104’s potential to complement existing therapies and drive meaningful progress against pancreatic cancer. Building on this momentum, we plan to expand the study to include additional arms, deepening our exploration of IMM-1-104’s potential for addressing critical oncology challenges. Our mission remains clear: to broaden indications and improve tolerability for cancer patients, bringing new hope where it’s needed most. 📢 Read the full press release here: https://buff.ly/3DJVUZn #CancerResearch #PancreaticCancer #MAPKPathway #SolidTumors #DrugDiscovery #ClinicalTrials #OncologyInnovation #MEKinhibitor

21

2 Comments

Life Sciences Year in Review — I had the pleasure of joining Zacks' John Vandermosten on this podcast to discuss market trends, potential innovation in life sciences, IPOs, M&A activity, and more. 🎧 Listen here: https://lnkd.in/gMNw-agY #Healthcare #Medicine #Podcasts #Biotech #Biopharma #Pharmaceuticals #CapitalMarkets

22

3 Comments

When building a company-wide approach to extending your Life Sciences cash runway, CFOs and leadership teams must do the following:    - Understand investor expectations - Spend cash on what matters - Evaluate different scenarios for funding growth - Focus on right now   Read more: https://lnkd.in/euJ4fVqX #lifesciencecfo #cashmanagement 

15

BOSTON--(BUSINESS WIRE)--Jun. 21, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented new data from its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). These updated data on 12 patients who received the full dose as a single infusion in Parts B and C of the trial are consistent with previously reported positive results in the VX-880 trial and reinforce the transformative potential of this therapy. More in the below news https://lnkd.in/dGCcnZqz

16

2 Comments

In 2024, Philadelphia's biopharma sector experienced significant milestones and faced notable challenges - reflect on the year in the The Philadelphia Inquirer's article (below). Notable highlights include accomplishments from PACT Members like Mineralys Therapeutics, Inc. and The Wistar Institute. Read more at https://lnkd.in/e6iEd8G3

2

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company, today unveiled new pharmacokinetic ("PK") data from its Phase 2a Eosinophilic Esophagitis ("#EoE") program. Management believes these data underscore the unique capabilities of Eupraxia's proprietary DiffuSphere™ platform technology, which aims to provide precise, localized, safe, and effective long-lasting drug delivery. Most conventional drugs release in a pattern characterized by steep peaks and rapid declines in drug concentration, where peaks often lead to negative side effects, and troughs result in reduced efficacy. In contrast, #DiffuSphere™ is a unique microsphere that is designed to enable #precisedrugrelease into target tissues with a flat, stable, and long-lasting profile, minimizing potential adverse events associated with high-dose systemic delivery. What sets DiffuSphere™ apart is its composition: a pure drug crystal encased in a microns-thick polymer shell. Eupraxia's #proprietary #technology uses this polymer to precisely control a drug's release, ensuring high drug concentrations in the target tissues while minimizing exposure to the rest of the body. This #innovative approach has been observed in Eupraxia's clinical programs, demonstrating precision, tolerability, and extended duration of delivering fluticasone propionate ("FP") directly to the intended tissues for EoE and knee osteoarthritis ("OA") patients. #biotech #pharma #investing #mergers https://lnkd.in/gX8fii4X

1

How do you empower your people to establish quality as a true asset?   In tomorrow's episode Hemish is joined by Sean Smith, VP Quality at KSQ Therapeutics, Inc. Sean started his journey with Amgen before moving to the East Coast and joining the Boston Biotech start-up world! His journey from big pharma to start-ups has benefited him from a technical standpoint, but his willingness to create a purpose-led culture within his team and the industry is what is really impressive.   We talk about the following:   🎤 Transitioning from big pharma to small biotech. 🎤 The mindset shift towards quality as an asset. 🎤 The evolution of quality philosophy. 🎤 The importance of purpose and why in quality leadership. 🎤 Developing individuals and instilling purpose in the team. 🎤 Career progression and options for quality leaders. You can watch live on Hemish's LinkedIn tomorrow at 8am EST to learn how to build a purpose-led quality unit that establish your team as a true asset to your organization!🔥  

39

2 Comments

How do you ensure your projects align with your organization's strategic vision? 🌐 Learn from Danette Astolfi, Senior Director of Project Management at Elevar Therapeutics, at our Boston conference. She'll discuss aligning projects and programs with business goals, sharing strategies from a leading pharmaceutical company. What challenges are you facing in strategic alignment? Let's find solutions together—reserve your seat today! https://lnkd.in/dmKigmrk #PPM #Boston #PharmaConference #StrategicAlignment

11

Breaking news! James Hussey, CEO at Seneca Therapeutics, Inc. will join The Keiretsu Family Office Forum as a part of the Family Office Investment Outlook Panel. Register now to hear his thoughts about the current landscape of family office investment: https://lnkd.in/dynZpRff #InvestorCapitalExpo #FamilyOfficeForum #AngelEcosystem #InvestorCapitalExpo2024 #AngelInvesting #AngelCommunity

2

Douglas Paul, VP of Commercial Strategy & Founder of Cypress BioPharma, and our President & CEO, Chris Smith, led a workshop recently at the 4th Annual Rare & Genetic Kidney Disease Drug & Development Summit in Boston titled, “Commercialization & Communication Through the Clinical Experience in the Rare & Genetic Kidney Disease Space.”   Doug and Chris outlined steps for understanding the needs of patient communities, communicating the value of promising treatments, and discussing drug prices in the context of today’s healthcare system. They explored reimbursement trends and surfaced ways to align payers, policy makers, physicians, and industry in a common goal of improving health.  #raredisease #genetherapy #kidneydisease

26

Join our webinar tomorrow at 12:00 PM to see how Allysta Pharmaceuticals is developing a completely new treatment for Duchenne Muscular Dystrophy, a genetic disease that affects men starting in childhood. https://hubs.la/Q02tLLgY0

1

Soligenix, Inc., a late-stage biopharmaceutical company focused on rare diseases, is participating in Spartan Capital Securities' inaugural investor conference on November 4th at the Pierre Hotel in New York. Christopher J. Schaber, PhD, President and CEO of Soligenix, expressed delight at the opportunity to present the company's accomplishments and future plans as it advances its rare disease pipeline. The conference, organized with B2i Digital, features over 30 companies, panel discussions, one-on-one meetings, and networking sessions. 'We're privileged to welcome Soligenix and showcase their accomplishments to our 950K+ sophisticated investor community across social media,' said David Shapiro, CEO of @b2idigital. John D. Lowry, Founder and CEO of @spartancapsec, emphasized the event's significance in commemorating Spartan Capital's 17 years in the capital markets and fostering connections between companies and investors. #investorrelations #biotechnology #rarediseases #soligenix #spartancapital #b2idigital

1

Eupraxia Pharmaciticals (NASDAQ: EPRX) One of three patients in Cohort 5 achieved complete histological remission at 12 weeks. Consistent improvement in patient-reported outcomes with six of six evaluable patients in the fourth and fifth cohorts experiencing a reduction in symptom (SDI1) scores at 12 weeks. At 24 weeks, the fourth cohort experienced the largest average reduction in SDI scores of all cohorts to date. The fifth cohort continued to show improved patient outcomes with the greatest percentage change in histology (EoEHSS2) scores of any cohort to date. Both the mean reduction in Peak Eosinophil Counts (PEC3)at four biopsy sites and the percent change in histology (EoEHSS2) scores showed a clear dose response across Cohorts 3 to 5, with Cohort 5 showing the greatest response. No serious adverse events reported in any of the five cohorts to date. Cohort 6 is now fully enrolled and dosed, with 12-week data anticipated in Q1 2025.

5

RApport's twice yearly analysis of biotech sector trends published today, with author Peter Kolchinsky noting that the first half of 2024 was a relatively quiet one for the public development-stage biotech universe, which has been gradually recovering from the last downturn. Do you know your Core from your Peripheral? How 2024 stacks up, M&A-wise, to prior years? How many years of free cash flow it would take the industry's strategic buyers to acquire the entire biotech universe for a 100% premium? Jump in to our Semper Maior report to find out. #biotech #M&A #financing #fixinsurance https://lnkd.in/ePywBE9C

35